Lenalidomidă Terapia (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, changing the complex’s target profile. This leads to the degradation of transcription factors Ikaros and Aiolos, which in turn reduces pro‑inflammatory cytokines, blocks new blood‑vessel formation, and enhances the activity of T‑ and natural‑killer cells, ultimately causing malignant cells to undergo apoptosis.

The exact dose of Lenalidomidă Terapia is individualized by the prescribing physician based on the specific indication, disease stage, patient’s renal and hepatic function, and concurrent therapies. Dosing is adjusted according to laboratory monitoring, especially blood‑cell counts, to balance efficacy with safety.

Lenalidomidă Terapia is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception, and the drug should not be used while breastfeeding, as it may be excreted in breast milk and affect the infant.

To request Lenalidomidă Terapia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug (IMiD) class, but lenalidomide is more potent, has a broader spectrum of activity, and generally exhibits a more favorable safety profile, especially regarding peripheral neuropathy. Lenalidomide also has stronger anti‑angiogenic and immune‑stimulating effects, making it the preferred choice for many of the approved indications.

Lenalidomidă Terapia should be stored at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use to maintain stability.

Lenalidomidă Terapia is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication is swallowed whole with a glass of water, and dosing schedules (e.g., daily or on specific days of a cycle) are determined by the treating physician based on the therapeutic plan.

The most serious risks include venous thromboembolism (blood clots), severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, significant liver toxicity, and profound neutropenia or thrombocytopenia that can lead to infections or bleeding. Patients should be monitored closely for these events throughout therapy.

Lenalidomidă Terapia is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled active infections. Caution is also advised for those with severe renal or hepatic impairment, and it should be avoided in patients receiving live vaccines.